<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000636</url>
  </required_header>
  <id_info>
    <org_study_id>CPCRA 004</org_study_id>
    <secondary_id>TB/PPD+</secondary_id>
    <secondary_id>ACTG 177</secondary_id>
    <secondary_id>11556</secondary_id>
    <nct_id>NCT00000636</nct_id>
  </id_info>
  <brief_title>Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection</brief_title>
  <official_title>Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate and compare the effectiveness of a 2-month regimen of rifampin and pyrazinamide&#xD;
      versus a 1-year course of isoniazid (INH) to prevent the development of tuberculosis in&#xD;
      patients who are coinfected with HIV and latent Mycobacterium tuberculosis (MTb).&#xD;
&#xD;
      Current guidelines recommend 6 to 12 months of treatment with INH for purified protein&#xD;
      derivative (PPD)-positive individuals. Problems with this treatment include compliance,&#xD;
      adverse reaction, and the possibility of not preventing disease due to INH-resistant&#xD;
      organisms. Studies suggest that two or three months of rifampin and pyrazinamide may be more&#xD;
      effective than longer courses of INH. A two-month prevention course should help to increase&#xD;
      compliance. In addition, the use of two drugs (rifampin and pyrazinamide) may help overcome&#xD;
      problems with drug resistance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current guidelines recommend 6 to 12 months of treatment with INH for purified protein&#xD;
      derivative (PPD)-positive individuals. Problems with this treatment include compliance,&#xD;
      adverse reaction, and the possibility of not preventing disease due to INH-resistant&#xD;
      organisms. Studies suggest that two or three months of rifampin and pyrazinamide may be more&#xD;
      effective than longer courses of INH. A two-month prevention course should help to increase&#xD;
      compliance. In addition, the use of two drugs (rifampin and pyrazinamide) may help overcome&#xD;
      problems with drug resistance.&#xD;
&#xD;
      After baseline screening, patients are randomized to one of two treatment arms and are&#xD;
      evaluated by means of clinic visits monthly for the first three months, then every three&#xD;
      months for the first year (there are additional clinic visits for INH patients). Patients are&#xD;
      then evaluated every six months. One group of patients takes INH plus vitamin B6 for 12&#xD;
      months. The other group of patients takes 1 of 2 doses of rifampin (depending on patient's&#xD;
      weight) plus pyrazinamide in 3-4 divided doses for 60 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">October 1997</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>2000</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrazinamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridoxine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiretroviral treatment.&#xD;
&#xD;
          -  Pneumocystis carinii pneumonia prophylaxis.&#xD;
&#xD;
          -  Treatment for acute opportunistic infection/malignancy.&#xD;
&#xD;
          -  Aminoglycosides, quinolones or fluoroquinolones such as ciprofloxacin or ofloxacin for&#xD;
             &lt; 14 days for treatment of intercurrent infection.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Reasonably good health at time of study entry.&#xD;
&#xD;
          -  Perceived life expectancy of at least six months.&#xD;
&#xD;
          -  Allowed:&#xD;
&#xD;
          -  Participation in other clinical trials as long as there is no potential activity of&#xD;
             other study drugs against Mycobacterium tuberculosis (MTb), additive toxicities&#xD;
             between study agents, or known possible drug interactions between study drugs.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Treatment with quinolones, fluoroquinolones, aminoglycosides, or other agents with&#xD;
             known or potential activity against M. tuberculosis.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Current active tuberculosis (confirmed or suspected).&#xD;
&#xD;
          -  Sensitivity or intolerance to study medication.&#xD;
&#xD;
          -  Acute hepatitis.&#xD;
&#xD;
          -  Evidence of peripheral neuropathy, i.e., signs or symptoms of paresis, paresthesias,&#xD;
             neuromotor abnormalities, or neurosensory deficits of grade 3 or worse.&#xD;
&#xD;
          -  Inability to have concomitant medications changed to avoid serious interaction with&#xD;
             study drug.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        -&#xD;
&#xD;
        Quinolones, fluoroquinolones, or aminoglycosides with antituberculous activity (may be used&#xD;
        for up to 14 days for treatment of intercurrent infection).Other agents with known or&#xD;
        potential antituberculous activity should be avoided, including the following:&#xD;
&#xD;
          -  Aminosalicylic acid salts, capreomycin, clofazimine, cycloserine, ethambutol,&#xD;
             ethionamide, isoniazid, kanamycin, pyrazinamide, rifabutin, rifampin, streptomycin,&#xD;
             and thiacetazone.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  History of treatment for &gt; 2 months with agents that have known or potential&#xD;
             antituberculous activity other than those specifically allowed.&#xD;
&#xD;
        Agents with potential or known antituberculous activity include the following:&#xD;
&#xD;
          -  Aminoglycosides such as amikacin, aminosalicylic acid salts, capreomycin,&#xD;
             ciprofloxacin, clofazimine, cycloserine, ethambutol, ethionamide, isoniazid,&#xD;
             kanamycin, ofloxacin, pyrazinamide, quinolones or fluoroquinolones, rifabutin,&#xD;
             rifampin, streptomycin, and thiacetazone.&#xD;
&#xD;
        Patients may not have:&#xD;
&#xD;
          -  Current active tuberculosis.&#xD;
&#xD;
          -  Acute hepatitis.&#xD;
&#xD;
          -  Peripheral neuropathy of grade 3 or grade 4.&#xD;
&#xD;
        Willing and able, in the clinician's opinion, to comply with the treatment and clinical&#xD;
        management issues.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordin F</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Brown LS</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Community Consortium / UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver CPCRA / Denver Public Hlth</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>802044507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hill Health Corp</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmington Hosp / Med Ctr of Delaware</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19899</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Med Ctr / Regional AIDS Program</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Dept of Health / Speciality STD Clinic</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Alliance - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Comm AIDS Rsch Prog / Tulane Univ Med</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Univ / Brazil</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Univ / School of Hygiene &amp; Public Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Dept of Health and Hosps</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive AIDS Alliance of Detroit</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hosp</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern New Jersey AIDS Cln Trials / Dept of Med</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Med Ctr</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lattimore Comprehensive Pulmonary Disease Clinic</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Jersey Community Research Initiative</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Lebanon Hosp Ctr</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addiction Research and Treatment Corp</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Directors Network of Region II</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem AIDS Treatment Group / Harlem Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia FIGHT</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond AIDS Consortium</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gordin F, Matts J, Miller C, Chaisson R, Garcia M, O'Brien R. Risk factors for developing active tuberculosis (TB) among HIV-infected, PPD-positive (+) patients (pts). Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4;6th:151 (abstract no 448)</citation>
  </reference>
  <reference>
    <citation>New TB guidelines for persons with HIV. AIDS Treat News. 1998 Nov 6;(No 306):6.</citation>
    <PMID>11365963</PMID>
  </reference>
  <reference>
    <citation>Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, Barry MA, O'Brien RJ. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA. 2000 Mar 15;283(11):1445-50. doi: 10.1001/jama.283.11.1445.</citation>
    <PMID>10732934</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Isoniazid</keyword>
  <keyword>Pyrazinamide</keyword>
  <keyword>Pyridoxine</keyword>
  <keyword>Rifampin</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antitubercular Agents</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

